Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
March 18, 2015
Clinical Trial Reveals Promising Brain Therapeutic Drug for the Pre-Dementia Stage of Alzheimer’s Disease
Pharmaceutical company AgeneBio recently announced the publication of results of a Phase 2 clinical trial based on the company’s therapeutic product AGB101 for the pre-dementia stage of Alzheimer’s disease in the journal NeuroImage: Clinical. The study entitled “Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance” was conducted by researchers at Johns Hopkins University in Baltimore and supported by the National Institutes of Health (NIH).
